A5090112161- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- HER2/EGFR in Cancer Research
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- COVID-19 Clinical Research Studies
- RNA modifications and cancer
- Metastasis and carcinoma case studies
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Ear and Head Tumors
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Cardiac Valve Diseases and Treatments
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
Istituti Ospitalieri di Cremona
2019-2025
Azienda Socio Sanitaria Territoriale di Cremona
2019-2025
Azienda Ospedaliera Universitaria Integrata Verona
2016-2019
University of Verona
2016-2019
Azienda Ospedaliero-Universitaria di Modena
2015-2018
University of Modena and Reggio Emilia
2016-2018
<div>AbstractPurpose:<p>We tested whether circulating tumor DNA (ctDNA) changes may be used to assess early response and clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line systemic anticancer therapy (SACT).</p>Experimental Design:<p>Eight hundred sixty-two plasma samples were collected 4-weekly from baseline (BL) until disease progression mCRC receiving SACT. ctDNA was using tissue-agnostic next-generation sequencing panels....
<p>Supp Table S2</p>
<p>Supp Table S3</p>
<p>Supp Tables</p>
<p>Supplementary Figures S1-S6</p>
<p>Supp Table S3</p>
<p>Supp Tables</p>
<p>Supp Table S2</p>
<p>Supplementary Figures S1-S6</p>
The spread of colorectal cancer screening has increased the percentage patients with early-stage rectal cancer; at least 30% are diagnosed a clinical-stage cT1 or pT1 after endoscopic excision. In this subgroup patients, real advantage total mesorectal excision (TME) over local (LE) is ability to remove nodes, which metastatic in less than 20% cases. To solve unmet need for accurate nodal staging cT0/cT1, cN0 cancer, we designed pilot study that associates LE fluorescence-guided sampling....
<b><i>Background:</i></b> Pulmonary sarcomatoid carcinoma is a rare, poorly differentiated, and highly aggressive type of non-small cell lung cancer. High tumor mutational burden PD-L1 overexpression make it an excellent candidate for immunotherapy. <b><i>Objectives Method:</i></b> We presented the case patient who underwent left inferior lobectomy with concurrent right paravertebral muscular metastasectomy infiltrative neoplastic mass, whose...
Abstract Purpose: we tested whether ctDNA changes may be used to assess early response and clinical outcome in metastatic colorectal cancer (mCRC) patients undergoing front-line systemic anti-cancer therapy (SACT). Experimental Design: 862 plasma samples were collected 4-weekly from baseline (BL) until disease progression mCRC receiving front line SACT. normalization was defined as ≥99% clearance after 1 month of (Mo1) the 3 variants with highest allele frequency BL ctDNA. Results: 83 paired...